Transcode Therapeutics Inc
NASDAQ:RNAZ
Income Statement
Earnings Waterfall
Transcode Therapeutics Inc
Income Statement
Transcode Therapeutics Inc
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(6)
|
(9)
|
(14)
|
(16)
|
(19)
|
(20)
|
(20)
|
(21)
|
(19)
|
(18)
|
(18)
|
(15)
|
(16)
|
(16)
|
(15)
|
(17)
|
|
| Selling, General & Administrative |
(3)
|
(5)
|
(7)
|
(7)
|
(8)
|
(9)
|
(9)
|
(9)
|
(7)
|
(6)
|
(6)
|
(5)
|
(6)
|
(5)
|
(5)
|
(5)
|
|
| Research & Development |
(3)
|
(4)
|
(7)
|
(9)
|
(10)
|
(11)
|
(11)
|
(12)
|
(12)
|
(11)
|
(12)
|
(9)
|
(10)
|
(10)
|
(10)
|
(12)
|
|
| Operating Income |
(6)
N/A
|
(9)
-49%
|
(14)
-47%
|
(16)
-19%
|
(19)
-16%
|
(20)
-8%
|
(20)
-2%
|
(21)
-2%
|
(19)
+7%
|
(18)
+8%
|
(18)
+0%
|
(15)
+18%
|
(16)
-7%
|
(16)
+1%
|
(15)
+6%
|
(17)
-16%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
(1)
|
3
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
|
| Gain/Loss on Disposition of Assets |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
1
|
1
|
1
|
2
|
1
|
1
|
1
|
0
|
0
|
(1)
|
(10)
|
(10)
|
(10)
|
|
| Pre-Tax Income |
(7)
N/A
|
(6)
+15%
|
(13)
-128%
|
(15)
-15%
|
(18)
-15%
|
(19)
-8%
|
(19)
+2%
|
(20)
-5%
|
(19)
+5%
|
(17)
+8%
|
(18)
-5%
|
(15)
+17%
|
(17)
-12%
|
(26)
-52%
|
(25)
+4%
|
(27)
-10%
|
|
| Net Income | |||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(7)
|
(6)
|
(13)
|
(15)
|
(18)
|
(19)
|
(19)
|
(20)
|
(19)
|
(17)
|
(18)
|
(15)
|
(17)
|
(26)
|
(25)
|
(27)
|
|
| Net Income (Common) |
(7)
N/A
|
(6)
+15%
|
(13)
-128%
|
(15)
-15%
|
(18)
-15%
|
(19)
-8%
|
(19)
+2%
|
(20)
-5%
|
(19)
+5%
|
(17)
+8%
|
(18)
-5%
|
(15)
+17%
|
(17)
-12%
|
(26)
-52%
|
(25)
+4%
|
(27)
-10%
|
|
| EPS (Diluted) |
-684 339.99
N/A
|
-291 409.99
+57%
|
-663 514.99
-128%
|
-761 509.99
-15%
|
-878 250
-15%
|
-945 589.99
-8%
|
-464 554.99
+51%
|
-163 271.66
+65%
|
-97 611.05
+40%
|
-3 062.11
+97%
|
-2 346.68
+23%
|
-939.37
+60%
|
-1 319.62
-40%
|
-148.28
+89%
|
-29.54
+80%
|
-32.58
-10%
|
|